Kobo Biotech Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Cost of Revenue	0	-	-	352.38	-
Gross Profit	-0	-	-	-352.38	-
Selling, General & Admin	1.99	2.48	2.3	7.15	13.93
Other Operating Expenses	8.6	5.79	7.16	-958.36	8.13
Operating Expenses	51.31	48.98	50.18	-173.59	78.43
Operating Income	-51.31	-48.98	-50.18	-178.79	-78.43
Interest Expense	-0	-	-	-1.34	-108
Interest & Investment Income	0.76	0.15	0.15	0.17	0.36
Currency Exchange Gain (Loss)	-1.74	-0.46	-5.51	-89.62	-5.83
Other Non Operating Income (Expenses)	-0	-0	-0	-0	-0.41
EBT Excluding Unusual Items	-52.3	-49.29	-55.53	-269.6	-192.31
Gain (Loss) on Sale of Investments	-	-	-	-121.93	-
Asset Writedown	-	-	-	-128.92	-
Other Unusual Items	-	-	-	368.19	-
Pretax Income	-52.3	-49.29	-55.53	-152.26	-192.31
Net Income	-52.3	-49.29	-55.53	-152.26	-192.31
Net Income to Common	-52.3	-49.29	-55.53	-152.26	-192.31
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	24	24	24	24	24
Shares Outstanding (Diluted)	24	24	24	24	24
Shares Change	-	-	-	-	0.04%
EPS (Basic)	-2.20	-2.07	-2.33	-6.39	-8.07
EPS (Diluted)	-2.20	-2.07	-2.33	-6.39	-8.07
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Free Cash Flow	41.75	2.04	8.75	937.57	25.09
Free Cash Flow Per Share	1.75	0.09	0.37	39.35	1.05
EBITDA	-10.68	-8.35	-9.54	-134.47	-22.06
D&A For EBITDA	40.63	40.63	40.64	44.32	56.37
EBIT	-51.31	-48.98	-50.18	-178.79	-78.43
Revenue as Reported	0.76	0.15	0.15	0.17	0.36
Advertising Expenses	0.12	-	-	-	-